1998
Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clinical Cancer Research 1998, 4: 1165-75. PMID: 9607574.Peer-Reviewed Original ResearchConceptsPreclinical studiesDose levelsUridine concentrationPhase I clinical trialGrade 1 constipationGrade 1 elevationGrade 1 fatigueGrade 1 feverGrade 2 anemiaOral dose levelsSingle oral doseTreatment of patientsPlasma uridine concentrationBiochemical end pointsFirst-order clearanceAverage peak concentrationCancer cell linesAdvanced cancerOral dosePlasma levelsPlasma uridineClinical trialsPlasma concentrationsSustained elevationTracer dose
1993
Microdialysis measurements of PGD2, TXB2 and 6-keto-PGF1α in rat CA1 hippocampus during transient cerebral ischemia
Huttemeier P, Kamiyama Y, Su M, Watkins W, Benveniste H. Microdialysis measurements of PGD2, TXB2 and 6-keto-PGF1α in rat CA1 hippocampus during transient cerebral ischemia. Prostaglandins 1993, 45: 177-187. PMID: 8430228, DOI: 10.1016/0090-6980(93)90033-4.Peer-Reviewed Original ResearchConceptsCerebral ischemiaPGF1 alphaMicrodialysis probeRat CA1 hippocampusGlobal cerebral ischemiaTransient cerebral ischemiaRole of PGD2Arachidonic acid metabolismAverage peak concentrationDistinct brain regionsIschemic brainEicosanoid concentrationsCA1 hippocampusEicosanoid releaseAA metabolitesPG metabolitesMicrodialysis measurementsBaseline levelsBrain regionsIschemiaPGD2TXB2Implanted microdialysis probesPeak concentrationAcid metabolism
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply